Id |
Subject |
Object |
Predicate |
Lexical cue |
T201 |
0-63 |
Sentence |
denotes |
6.1 Effect of cross-reactive antibodies on SARS-CoV-2 pandemic |
T202 |
64-230 |
Sentence |
denotes |
Due to the high similarity of S proteins from SARS-CoV and MERS-CoV [73], their specific cross-nAbs were tested against SARS-CoV-2 infection in the COVID-19 outbreak. |
T203 |
231-375 |
Sentence |
denotes |
Serum Abs from recovered SARS-CoV patients could efficiently cross-neutralize SARS-CoV-2 but with lower efficiency as compared to SARS-CoV [92]. |
T204 |
376-459 |
Sentence |
denotes |
Cross-reactive Abs against SARS-CoV-2 S protein mostly target non-RBD regions [93]. |
T205 |
460-635 |
Sentence |
denotes |
Using simulation technique, the binding of five Abs against SARS-CoV, six Abs anti-MERS-CoV to RBD of SARS-CoV-2 was predicted with Rosetta antibody-antigen docking protocols. |
T206 |
636-749 |
Sentence |
denotes |
The amino acid position 445–449 (VGGNY) and 470–486 (TEIYQAGSTPCNGVEGF) were found to be conserved in SARS-CoV-2. |
T207 |
750-918 |
Sentence |
denotes |
Moreover, in addition to the amino acid positions 71–77 (GTNGTKR) in the NTD region of the S protein, aa 445–449 and 470–486 are potential for further development [94]. |
T208 |
919-1011 |
Sentence |
denotes |
The difference between RBD of SARS-CoV and SARS-CoV-2 is located at the C-terminus residues. |
T209 |
1012-1080 |
Sentence |
denotes |
This change has an important impact on the cross-reactivity of nAbs. |
T210 |
1081-1161 |
Sentence |
denotes |
This difference was observed using bioinformatic approaches of epitope analysis. |
T211 |
1162-1227 |
Sentence |
denotes |
The antibody epitope score of SARS-CoV-2 is higher than SARS-CoV. |
T212 |
1228-1431 |
Sentence |
denotes |
Moreover, compared with the conserved regions, the non-conserved regions had a significantly higher antibody epitope score indicating that non-conserved regions of spike proteins are much more antigenic. |
T213 |
1432-1613 |
Sentence |
denotes |
The non-conserved regions also showed significantly higher surface epitope accessibility scores suggesting an easier accessibility for antibody recognition of non-conserved regions. |
T214 |
1614-1704 |
Sentence |
denotes |
The divergence of spike proteins is considered as a major change in the antibody epitopes. |
T215 |
1705-1799 |
Sentence |
denotes |
The search for SARS-CoV-2 requires more effort than simply screening SARS-CoV antibodies [95]. |
T216 |
1800-1851 |
Sentence |
denotes |
Antibody response to RBD is viral species-specific. |
T217 |
1852-1986 |
Sentence |
denotes |
Effectively, none of the found SARS-CoV-2 antibodies nor the infected plasma cross-reacted with RBDs from either SARS-CoV or MERS-CoV. |
T218 |
1987-2090 |
Sentence |
denotes |
In a study, 206 monoclonal antibodies specific to the RBD SARS-CoV-2 were identified in eight patients. |
T219 |
2091-2243 |
Sentence |
denotes |
These mAbs are different in: antibody heavy and light chains, antibody clones, CDR3 length… which lead to different binding and neutralizing capacities. |
T220 |
2244-2335 |
Sentence |
denotes |
ACE2 is out-competed with almost 100% efficacity by some mAbs such as P2B-2F6 and P2C-1F11. |
T221 |
2336-2499 |
Sentence |
denotes |
Interestingly the latter and a moderate antibody P2C-1C10 seems to target the different epitopes, and they could be combined for synergistic antiviral effect [96]. |
T222 |
2500-2667 |
Sentence |
denotes |
CR3022, a SARS-CoV RBD-specific antibody, can bind strongly with a kd of 6.3 nM to an epitope on RBD that does not overlap with the SARS-Cov-2 ACE-2 binding site [34]. |
T223 |
2668-2740 |
Sentence |
denotes |
Despite its strong binding, CR3022 could not neutralize SARS-CoV-2 [97]. |
T224 |
2741-2798 |
Sentence |
denotes |
S1 is a specific antigen for SARS-CoV-2 diagnostics [98]. |
T225 |
2799-2878 |
Sentence |
denotes |
The S1 subunit of SARS-CoV or SARS-CoV-2 has four core domains S1A through S1D. |
T226 |
2879-3139 |
Sentence |
denotes |
The human 47D11 antibody binds the S1B of both viruses, without competing with S1B binding to ACE2 receptor expressed at the cell surface, and showed cross-neutralizing activity by an unknown mechanism that is different from receptor binding interference [99]. |
T227 |
3140-3263 |
Sentence |
denotes |
An immunogenic domain in the S2 subunit of SARS-CoV S (aa 1029–1192) was highly conserved in several strains of SARS-CoV-2. |
T228 |
3264-3410 |
Sentence |
denotes |
Four murine monoclonal Abs, 1A9, 1G10, 2B2 and 4B12, against this S2 subunit of SARS-CoV can also cross-reactive with the S protein of SARS-CoV-2. |
T229 |
3411-3578 |
Sentence |
denotes |
Interestingly, 1A9 can strongly bind the S2 subunit of SARS-CoV-2 through a novel epitope (aa 1111–1130) and can detect S protein in SARS-CoV-2 during infection [100]. |
T230 |
3579-3710 |
Sentence |
denotes |
This epitope also overlaps with one of two cytotoxic T-lymphocyte epitopes (aa 884–891 and 1116–1123) of SARS-CoV S2 subunit [101]. |
T231 |
3711-3823 |
Sentence |
denotes |
1A9 is therefore suggested to induce both humoral and cellular immune responses against SARS-CoV and SARS-CoV-2. |
T232 |
3824-4053 |
Sentence |
denotes |
In a serologic cross-reactivity test, Khan et al. found out that 4 out of 5 showed high IgG seroreactivity across the 4 common human coronaviruses but all showed low IgG seroreactivity to SARS-CoV-2, SARS-CoV, and MERS-CoV [102]. |
T233 |
4054-4257 |
Sentence |
denotes |
The weak cross-immunity against SARS-CoV-2 from others betacoronaviruses, such as HCoV-OC43 and HCoV-HKU1, could restraint the transmission of SARS-CoV-2 but a resurgence is possible in the future [103]. |
T234 |
4258-4412 |
Sentence |
denotes |
Moreover, spike- and non-spike specific CD4+ T cell responses were detectable not only in SARS-CoV-2 infected patients but also in uninfected individuals. |
T235 |
4413-4604 |
Sentence |
denotes |
If there is an absence of antibody cross-reactivity, T lymphocyte cross-reactivity present in 50% of cases will be responsible for the epidemiological evolution of SARS-CoV-2 infection [104]. |